Restricted accessResearch articleFirst published online 2012-09
Differentiation and Transplantation of Functional Pancreatic Beta Cells Generated from Induced Pluripotent Stem Cells Derived from a Type 1 Diabetes Mouse Model
The nonobese diabetic (NOD) mouse is a classical animal model for autoimmune type 1 diabetes (T1D), closely mimicking features of human T1D. Thus, the NOD mouse presents an opportunity to test the effectiveness of induced pluripotent stem cells (iPSCs) as a therapeutic modality for T1D. Here, we demonstrate a proof of concept for cellular therapy using NOD mouse-derived iPSCs (NOD-iPSCs). We generated iPSCs from NOD mouse embryonic fibroblasts or NOD mouse pancreas-derived epithelial cells (NPEs), and applied directed differentiation protocols to differentiate the NOD-iPSCs toward functional pancreatic beta cells. Finally, we investigated whether the NPE-iPSC-derived insulin-producing cells could normalize hyperglycemia in transplanted diabetic mice. The NOD-iPSCs showed typical embryonic stem cell-like characteristics such as expression of markers for pluripotency, in vitro differentiation, teratoma formation, and generation of chimeric mice. We developed a method for stepwise differentiation of NOD-iPSCs into insulin-producing cells, and found that NPE-iPSCs differentiate more readily into insulin-producing cells. The differentiated NPE-iPSCs expressed diverse pancreatic beta cell markers and released insulin in response to glucose and KCl stimulation. Transplantation of the differentiated NPE-iPSCs into diabetic mice resulted in kidney engraftment. The engrafted cells responded to glucose by secreting insulin, thereby normalizing blood glucose levels. We propose that NOD-iPSCs will provide a useful tool for investigating genetic susceptibility to autoimmune diseases and generating a cellular interaction model of T1D, paving the way for the potential application of patient-derived iPSCs in autologous beta cell transplantation for treating diabetes.
Get full access to this article
View all access options for this article.
References
1.
DeruytterN, BoulardO, GarchonHJ. 2004. Mapping non-class II H2-linked loci for type 1 diabetes in nonobese diabetic mice. Diabetes, 53:3323–3327.
2.
1997. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20:1183–1197.
LakeyJR, MirbolookiM, ShapiroAM. 2006. Current status of clinical islet cell transplantation. Methods Mol Biol, 333:47–104.
5.
RobertsonRP, HolohanTV, GenuthS. 1998. Therapeutic controversy: pancreas transplantation for type I diabetes. J Clin Endocrinol Metab, 83:1868–1874.
6.
ShapiroAM, LakeyJR, RyanEA, KorbuttGS, TothE, WarnockGL, KnetemanNM, RajotteRV. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 343:230–238.
7.
HeringBJ, WijkstromM, GrahamML, HardstedtM, AasheimTC, JieT, AnsiteJD, NakanoM, ChengJet al.2006. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med, 12:301–303.
8.
HechtG, Eventov-FriedmanS, RosenC, ShezenE, TchorshD, AronovichA, FreudE, GolanH, El-HasidRet al.2009. Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci U S A, 106:8659–8664.
9.
D'AmourKA, BangAG, EliazerS, KellyOG, AgulnickAD, SmartNG, MoormanMA, KroonE, CarpenterMK, BaetgeEE. 2006. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol, 24:1392–1401.
10.
KroonE, MartinsonLA, KadoyaK, BangAG, KellyOG, EliazerS, YoungH, RichardsonM, SmartNGet al.2008. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol, 26:443–452.
11.
TyndallA, WalkerUA, CopeA, DazziF, De BariC, FibbeW, GuiducciS, JonesS, JorgensenCet al.2007. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther, 9:301.
12.
MorigiM, ImbertiB, ZojaC, CornaD, TomasoniS, AbbateM, RottoliD, AngiolettiS, BenigniAet al.2004. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol, 15:1794–1804.
13.
DuffieldJS, ParkKM, HsiaoLL, KelleyVR, ScaddenDT, IchimuraT, BonventreJV. 2005. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest, 115:1743–1755.
14.
AbdiR, FiorinaP, AdraCN, AtkinsonM, SayeghMH. 2008. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 57:1759–1767.
15.
CampDM, LoefflerDA, FarrahDM, BornemanJN, LeWittPA. 2009. Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease. J Neuroinflammation, 6:17.
LeeCH, KimEY, JeonK, TaeJC, LeeKS, KimYO, JeongMY, YunCW, JeongDKet al.2008. Simple, efficient, and reproducible gene transfection of mouse embryonic stem cells by magnetofection. Stem Cells Dev, 17:133–141.
18.
TakahashiK, YamanakaS. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126:663–676.
19.
RubinLL. 2008. Stem cells and drug discovery: the beginning of a new era?Cell, 132:549–552.
20.
AndersonMS, BluestoneJA. 2005. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol, 23:447–485.
21.
WickerLS, ClarkJ, FraserHI, GarnerVE, Gonzalez-MunozA, HealyB, HowlettS, HunterK, RainbowDet al.2005. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun, 25,Suppl:29–33.
22.
AtkinsonMA, LeiterEH. 1999. The NOD mouse model of type 1 diabetes: as good as it gets?Nat Med, 5:601–604.
23.
DelovitchTL, SinghB. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity, 7:727–738.
24.
LakeyJR, SinghB, WarnockGL, RajotteRV. 1994. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation, 57:1213–1217.
WangT, SinghB, WarnockGL, RajotteRV. 1992. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes, 41:114–117.
27.
RyuS, KodamaS, RyuK, SchoenfeldDA, FaustmanDL. 2001. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J Clin Invest, 108:63–72.
28.
RabinovitchA, Suarez-PinzonWL, ShapiroAM, RajotteRV, PowerR. 2002. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes, 51:638–645.
29.
WuQ, SalomonB, ChenM, WangY, HoffmanLM, BluestoneJA, FuYX. 2001. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med, 193:1327–1332.
30.
GregoriS, GiarratanaN, SmiroldoS, UskokovicM, AdoriniL. 2002. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes, 51:1367–1374.
31.
Bertry-CoussotL, LucasB, DanelC, Halbwachs-MecarelliL, BachJF, ChatenoudL, LemarchandP. 2002. Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol, 168:3641–3648.
32.
RayatGR, SinghB, KorbuttGS, RajotteRV. 2000. Single injection of insulin delays the recurrence of diabetes in syngeneic islet-transplanted diabetic NOD mice. Transplantation, 70:976–979.
33.
SandbergJO, EizirikDL, SandlerS. 1997. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol, 108:314–317.
BoltonWE, TerrellSP, AndrewsKL, BoydAE. 1982. Preparation of primary monolayer cultures of mouse pancreatic epithelial cells. Methods Cell Sci, 7:39–42.
36.
LeeCH, KimJH, LeeHJ, JeonK, LimH, ChoiH, LeeER, ParkSH, ParkJYet al.2011. The generation of iPS cells using non-viral magnetic nanoparticle based transfection. Biomaterials, 32:6683–6691.
37.
YamadaT, YoshikawaM, KandaS, KatoY, NakajimaY, IshizakaS, TsunodaY. 2002. In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. Stem Cells, 20:146–154.
38.
NiwaH, MiyazakiJ, SmithAG. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet, 24:372–376.
39.
LivakKJ, SchmittgenTD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25:402–408.
40.
MaehrR, ChenS, SnitowM, LudwigT, YagasakiL, GolandR, LeibelRL, MeltonDA. 2009. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A, 106:15768–15773.
41.
ZhangD, JiangW, LiuM, SuiX, YinX, ChenS, ShiY, DengH. 2009. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res, 19:429–438.
KimYH, KimS, KimKA, YagitaH, KayagakiN, KimKW, LeeMS. 1999. Apoptosis of pancreatic beta-cells detected in accelerated diabetes of NOD mice: no role of Fas-Fas ligand interaction in autoimmune diabetes. Eur J Immunol, 29:455–465.
44.
HannaJ, MarkoulakiS, MitalipovaM, ChengAW, CassadyJP, StaerkJ, CareyBW, LengnerCJ, ForemanRet al.2009. Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell, 4:513–524.
45.
TeitelmanG, AlpertS, PolakJM, MartinezA, HanahanD. 1993. Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development, 118:1031–1039.
46.
HaydenEC. 2011. Stem cells: the growing pains of pluripotency. Nature, 473:272–274.
Bar-NurO, RussHA, EfratS, BenvenistyN. 2011. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet Beta cells. Cell Stem Cell, 9:17–23.
53.
AlyanakianMA, YouS, DamotteD, GouarinC, EslingA, GarciaC, HavouisS, ChatenoudL, BachJF. 2003. Diversity of regulatory CD4+ T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A, 100:15806–15811.
54.
WuO, ChenGP, ChenH, LiXP, XuJH, ZhaoSS, ShengJ, FengJB, CaiJet al.2009. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology, 214:392–402.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
